Status | Study |
Completed |
Study Name: Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca Condition: Keratoconjunctivitis Sicca Dry Eye Date: 2013-02-21 Interventions: Drug: dexamethasone, artificial tears |
Completed |
Study Name: A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease Condition: Keratoconjunctivitis Sicca Date: 2012-11-21 Interventions: Drug: R348 Ophthalmic Solution, 0.2% |
Completed |
Study Name: Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) Condition: Dry Eye Keratoconjunctivitis Sicca Date: 2011-08-17 Interventions: Drug: Lifitegrast Dosage Form: |
Completed |
Study Name: Trial of CF101 to Treat Patients With Dry Eye Disease Condition: Keratoconjunctivitis Sicca Date: 2010-11-03 Interventions: Drug: CF101 orally q12h Other Name: IB-MECA |
Withdrawn |
Study Name: A Study Of Tasocitinib In Dry Eye Subjects Condition: Keratoconjunctivitis Sicca Date: 2010-10-20 Interventions: Drug: Tasocitinib 0.005% QD fo |
Terminated |
Study Name: Omega-3 Fatty Acid Supplements and Dry Eye Condition: Keratoconjunctivitis Sicca Date: 2010-09-30 Interventions: Dietary Supplement: Omega-3 Fatty Acid |
Completed |
Study Name: Dry Eye Assessment and Management: Feasibility Study Condition: Dry Eye Syndromes Keratoconjunctivitis Si Date: 2010-04-09 Interventions: Drug: Omega-3 EFA Supplement |
Completed |
Study Name: Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye Condition: Keratoconjunctivitis Sicca Date: 2009-04-17 Interventions: Dietary Supplement: Hydroeye 2 |
Completed |
Study Name: A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) Condition: Keratoconjunctivitis Sicca Date: 2009-02-24 Interventions: Drug: voclosporin ophthalmic solution 0.02%, 0.2% t.i.d. or b.i.d. |
Completed |
Study Name: TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease Condition: Keratoconjunctivitis Sicca Date: 2009-02-18 |